Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib

SIMPLE SUMMARY: Afatinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used to treat patients with advanced EGFR-mutant lung cancer. In this study, we retrospectively enrolled patients with lung adenocarcinomas harboring susceptible EGFR mutations, who we...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsai, Ming-Ju, Hung, Jen-Yu, Ma, Juei-Yang, Tsai, Yu-Chen, Wu, Kuan-Li, Lee, Mei-Hsuan, Kuo, Chia-Yu, Chuang, Cheng-Hao, Lee, Tai-Huang, Lee, Yen-Lung, Huang, Chun-Ming, Shen, Mei-Chiou, Yang, Chih-Jen, Chong, Inn-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092956/
https://www.ncbi.nlm.nih.gov/pubmed/37046679
http://dx.doi.org/10.3390/cancers15072019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092956/
https://www.ncbi.nlm.nih.gov/pubmed/37046679
http://dx.doi.org/10.3390/cancers15072019

Ejemplares similares